查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1193135

奧氮平市場：按應用、給藥途徑和分銷渠道分類：2021-2031 年全球機遇分析和行業預測

Olanzapine Market By Application, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 229 Pages | 商品交期: 2-3個工作天內

價格

奧氮平是一種非典型抗精神病藥物，主要用於治療精神分裂症和雙相情感障礙。

它有片劑、注射劑和崩解片形式。 平衡多巴胺和血清素，以增強認知、情緒和行為。 奧氮平用於治療精神分裂症的症狀，精神分裂症是一種精神障礙，會導致成人和 13 歲以上的青少年出現思想障礙、奇怪的想法、對生活失去興趣以及強烈或不適當的情緒。 它還用於治療雙相情感障礙，這是一種躁狂抑鬱發作，會導致成人和 13 歲以上青少年出現躁狂、悲傷和其他異常情緒。

世界衛生組織 (WHO) 推薦心理健康行動計劃，以促進成員國的心理健康和預防精神障礙。 根據世界衛生組織的關鍵數據，全世界估計有 3 億人患有抑鬱症，6000 萬人患有躁鬱症。 焦慮症是影響兒童和成人的最常見精神疾病。 估計有 4400 萬美國成年人受到焦慮症的影響。 儘管是一種高度可治療的疾病，但只有大約三分之一的焦慮症患者接受治療。 因此，這個市場主要是由精神疾病患病率上升驅動的。

奧氮平全球市場的增長主要受全球精神分裂症患病率上升的推動。 例如，根據世界衛生組織 (WHO) 的數據，到 2022 年 1 月，全球約有 2400 萬人，即每 300 人中就有 1 人 (0.32%) 會受到精神分裂症的影響。 此外，由於缺乏衛生和預防措施，醫院獲得性感染 (HAI) 的增加是市場增長的主要驅動力。 此外，精神病診所的增加和醫療基礎設施的發展也有助於市場擴張。 然而，奧氮平的高價格和副作用阻礙了市場增長。 相反，主要參與者對奧氮平產品的認可度增加以及新興經濟體的高增長潛力有望為市場參與者提供有利可圖的機會。 例如，2021 年 6 月，全球生物製藥公司 Alkermes plc. 獲得美國食品和藥物管理局 (FDA) 的 LYBALVI（奧氮平和沙米多芬）作為治療躁狂或混合發作的急性治療藥物。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特的五力分析
  • 主要公司的定位
  • 市場動態
    • 司機
    • 約束因素
    • 機會
  • 分析 COVID-19 對市場的影響

第 4 章奧氮平市場：按應用

  • 概覽
    • 市場規模和預測
  • 精神分裂症
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 躁鬱症
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 5 章奧氮平市場：按給藥途徑分類

  • 概覽
    • 市場規模和預測
  • 口語
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 腸外
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 6 章奧氮平市場：按分銷渠道

  • 概覽
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 藥店、零售藥店
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 在線提供商
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 7 章奧氮平市場：按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機會
    • 北美市場規模和預測：按應用
    • 北美市場規模和預測：按給藥途徑
    • 北美市場規模和預測：按分銷渠道
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機會
    • 歐洲市場規模和預測：按應用分類
    • 歐洲市場規模和預測：按給藥途徑
    • 歐洲市場規模和預測：按分銷渠道
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲地區
  • 亞太地區
    • 主要趨勢和機會
    • 亞太市場規模和預測：按應用
    • 按給藥途徑劃分的亞太地區市場規模和預測
    • 亞太市場規模和預測：按分銷渠道
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 日本
      • 中國
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
  • 拉美
    • 主要趨勢和機會
    • LAMEA 市場規模和預測：按應用分類
    • LAMEA 市場規模和預測：按給藥途徑
    • LAMEA 市場規模和預測：按分銷渠道
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其餘部分

第八章公司情況

  • 介紹
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 主要發展

第九章公司簡介

  • Alkermes, Inc.
  • apotex inc.
  • Aurobindo Pharma Ltd
  • Eli Lilly and Company
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Limited
  • Torrent Group
  • Teva Pharmaceutical Industries Limited
  • Novartis AG
  • Viatris
Product Code: A15452

Olanzapine is an atypical antipsychotic drug, primarily used to treat schizophrenia and bipolar disorder. It is available in the form of a tablet, injectable, and a disintegrating tablet. It balances dopamine and serotonin to enhance cognition, mood, and behavior. Olanzapine is used to treat the symptoms of schizophrenia, which is a mental condition that causes disturbed or strange thinking, loss of interest in life, and strong or inappropriate emotions, in adults and teenagers 13 years of age and older. It is also used to treat bipolar disorder, which is a manic-depressive disorder, a condition that produces episodes of mania, sadness, and other abnormal moods, in adults and adolescents 13 years of age and older.

World Health Organization (WHO) has recommended mental health action plan to promote mental health and prevent mental disorders in the member states. In addition, according to the key facts published by the WHO, an estimated 300 million people are affected by depression, and 60 million people are affected by bipolar disorder, across the globe. Anxiety disorders are the most communal psychiatric illnesses affecting children and adults. It is evaluated that 44 million American grown-ups experience ill effects of uneasiness issue. Merely, about one-third of those suffering from an anxiety disorder receive treatment, even though the disorders are highly treatable. Therefore, it is indicated that the market is majorly driven by rise in prevalence of mental disorders.

The growth of global olanzapine market is majorly driven by rise in prevalence of schizophrenia globally. For instance, in January 2022, according to World Health Organization (WHO), schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) globally. In addition, increase in cases of Hospital Acquired Infections (HAI), owing to lack of sanitation and preventive measures, is a major factor responsible for the market growth. Furthermore, rise in the number of mental disorder clinics and improvement in healthcare infrastructure further contribute in the market growth. However, high cost of olanzapine and side effects of olanzapine hinder the market growth. Conversely, rise in product approvals for olanzapine in market by key players and high growth potential in developing economies are anticipated to provide lucrative opportunities to the market players. For instance, in June 2021, Alkermes plc., a global biopharmaceutical company, received U.S. Food and Drug Administration (FDA) for its LYBALVI (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate.

The olanzapine market is segmented into application, route of administration, distribution channel, and region. On the basis of application, the market is segregated into schizophrenia, bipolar disorders, and others. By route of administration, the market is segmented into oral and parenteral. On the basis of distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global olanzapine market are Alkermes, Apotex Inc., Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Torrent Power Ltd, and Viatris Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the olanzapine market analysis from 2021 to 2031 to identify the prevailing olanzapine market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the olanzapine market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global olanzapine market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Application

  • Bipolar Disorder
  • Others
  • Schizophrenia

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Drug stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Alkermes, Inc.
    • apotex inc.
    • Aurobindo Pharma Ltd
    • Eli Lilly and Company
    • Dr. Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries Limited
    • Torrent Group
    • Teva Pharmaceutical Industries Limited
    • Novartis AG
    • Viatris

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: OLANZAPINE MARKET, BY APPLICATION

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Schizophrenia
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Bipolar Disorder
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country
  • 4.4 Others
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market share analysis by country

CHAPTER 5: OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Oral
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Parenteral
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country

CHAPTER 6: OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Drug stores and Retail Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country
  • 6.4 Online Providers
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market share analysis by country

CHAPTER 7: OLANZAPINE MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Application
    • 7.2.3 North America Market size and forecast, by Route of Administration
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Key market trends, growth factors and opportunities
      • 7.2.5.1.2 Market size and forecast, by Application
      • 7.2.5.1.3 Market size and forecast, by Route of Administration
      • 7.2.5.1.4 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Key market trends, growth factors and opportunities
      • 7.2.5.2.2 Market size and forecast, by Application
      • 7.2.5.2.3 Market size and forecast, by Route of Administration
      • 7.2.5.2.4 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Key market trends, growth factors and opportunities
      • 7.2.5.3.2 Market size and forecast, by Application
      • 7.2.5.3.3 Market size and forecast, by Route of Administration
      • 7.2.5.3.4 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Application
    • 7.3.3 Europe Market size and forecast, by Route of Administration
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Key market trends, growth factors and opportunities
      • 7.3.5.1.2 Market size and forecast, by Application
      • 7.3.5.1.3 Market size and forecast, by Route of Administration
      • 7.3.5.1.4 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Key market trends, growth factors and opportunities
      • 7.3.5.2.2 Market size and forecast, by Application
      • 7.3.5.2.3 Market size and forecast, by Route of Administration
      • 7.3.5.2.4 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Key market trends, growth factors and opportunities
      • 7.3.5.3.2 Market size and forecast, by Application
      • 7.3.5.3.3 Market size and forecast, by Route of Administration
      • 7.3.5.3.4 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Key market trends, growth factors and opportunities
      • 7.3.5.4.2 Market size and forecast, by Application
      • 7.3.5.4.3 Market size and forecast, by Route of Administration
      • 7.3.5.4.4 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Key market trends, growth factors and opportunities
      • 7.3.5.5.2 Market size and forecast, by Application
      • 7.3.5.5.3 Market size and forecast, by Route of Administration
      • 7.3.5.5.4 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Key market trends, growth factors and opportunities
      • 7.3.5.6.2 Market size and forecast, by Application
      • 7.3.5.6.3 Market size and forecast, by Route of Administration
      • 7.3.5.6.4 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Application
    • 7.4.3 Asia-Pacific Market size and forecast, by Route of Administration
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Key market trends, growth factors and opportunities
      • 7.4.5.1.2 Market size and forecast, by Application
      • 7.4.5.1.3 Market size and forecast, by Route of Administration
      • 7.4.5.1.4 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Key market trends, growth factors and opportunities
      • 7.4.5.2.2 Market size and forecast, by Application
      • 7.4.5.2.3 Market size and forecast, by Route of Administration
      • 7.4.5.2.4 Market size and forecast, by Distribution Channel
      • 7.4.5.3 India
      • 7.4.5.3.1 Key market trends, growth factors and opportunities
      • 7.4.5.3.2 Market size and forecast, by Application
      • 7.4.5.3.3 Market size and forecast, by Route of Administration
      • 7.4.5.3.4 Market size and forecast, by Distribution Channel
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Key market trends, growth factors and opportunities
      • 7.4.5.4.2 Market size and forecast, by Application
      • 7.4.5.4.3 Market size and forecast, by Route of Administration
      • 7.4.5.4.4 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Key market trends, growth factors and opportunities
      • 7.4.5.5.2 Market size and forecast, by Application
      • 7.4.5.5.3 Market size and forecast, by Route of Administration
      • 7.4.5.5.4 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Key market trends, growth factors and opportunities
      • 7.4.5.6.2 Market size and forecast, by Application
      • 7.4.5.6.3 Market size and forecast, by Route of Administration
      • 7.4.5.6.4 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Application
    • 7.5.3 LAMEA Market size and forecast, by Route of Administration
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Key market trends, growth factors and opportunities
      • 7.5.5.1.2 Market size and forecast, by Application
      • 7.5.5.1.3 Market size and forecast, by Route of Administration
      • 7.5.5.1.4 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Key market trends, growth factors and opportunities
      • 7.5.5.2.2 Market size and forecast, by Application
      • 7.5.5.2.3 Market size and forecast, by Route of Administration
      • 7.5.5.2.4 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Key market trends, growth factors and opportunities
      • 7.5.5.3.2 Market size and forecast, by Application
      • 7.5.5.3.3 Market size and forecast, by Route of Administration
      • 7.5.5.3.4 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Key market trends, growth factors and opportunities
      • 7.5.5.4.2 Market size and forecast, by Application
      • 7.5.5.4.3 Market size and forecast, by Route of Administration
      • 7.5.5.4.4 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Alkermes, Inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 apotex inc.
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Aurobindo Pharma Ltd
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Eli Lilly and Company
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Dr. Reddy's Laboratories Ltd.
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Sun Pharmaceutical Industries Limited
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Torrent Group
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Teva Pharmaceutical Industries Limited
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Novartis AG
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Viatris
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 2. OLANZAPINE MARKET FOR SCHIZOPHRENIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 3. OLANZAPINE MARKET FOR SCHIZOPHRENIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 4. OLANZAPINE MARKET FOR BIPOLAR DISORDER, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 5. OLANZAPINE MARKET FOR BIPOLAR DISORDER, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 6. OLANZAPINE MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 7. OLANZAPINE MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 8. GLOBAL OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 9. OLANZAPINE MARKET FOR ORAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. OLANZAPINE MARKET FOR ORAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. OLANZAPINE MARKET FOR PARENTERAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. OLANZAPINE MARKET FOR PARENTERAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. GLOBAL OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. OLANZAPINE MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. OLANZAPINE MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. OLANZAPINE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. OLANZAPINE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. OLANZAPINE MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. OLANZAPINE MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. OLANZAPINE MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. NORTH AMERICA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. NORTH AMERICA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. NORTH AMERICA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. NORTH AMERICA OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. U.S. OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. U.S. OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. U.S. OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. CANADA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. CANADA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. CANADA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. MEXICO OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. MEXICO OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. MEXICO OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. EUROPE OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. EUROPE OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. EUROPE OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. EUROPE OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. GERMANY OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. GERMANY OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. GERMANY OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. FRANCE OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. FRANCE OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. FRANCE OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. UK OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. UK OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. UK OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. ITALY OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. ITALY OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. ITALY OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. SPAIN OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. SPAIN OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. SPAIN OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. REST OF EUROPE OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. REST OF EUROPE OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. REST OF EUROPE OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. ASIA-PACIFIC OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. ASIA-PACIFIC OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. ASIA-PACIFIC OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. ASIA-PACIFIC OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. JAPAN OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. JAPAN OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. JAPAN OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. CHINA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. CHINA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. CHINA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. INDIA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. INDIA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. INDIA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. AUSTRALIA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. AUSTRALIA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. AUSTRALIA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. SOUTH KOREA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. SOUTH KOREA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. SOUTH KOREA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. REST OF ASIA-PACIFIC OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. REST OF ASIA-PACIFIC OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. REST OF ASIA-PACIFIC OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. LAMEA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. LAMEA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. LAMEA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. LAMEA OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. BRAZIL OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. BRAZIL OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. BRAZIL OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. SAUDI ARABIA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. SAUDI ARABIA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. SAUDI ARABIA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. SOUTH AFRICA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 89. SOUTH AFRICA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 90. SOUTH AFRICA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 91. REST OF LAMEA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 92. REST OF LAMEA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 93. REST OF LAMEA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 94.ALKERMES, INC.: COMPANY SNAPSHOT
  • TABLE 95.ALKERMES, INC.: OPERATING SEGMENTS
  • TABLE 96.ALKERMES, INC.: PRODUCT PORTFOLIO
  • TABLE 97.ALKERMES, INC.: NET SALES
  • TABLE 98.ALKERMES, INC.: KEY STRATERGIES
  • TABLE 99.APOTEX INC.: COMPANY SNAPSHOT
  • TABLE 100.APOTEX INC.: OPERATING SEGMENTS
  • TABLE 101.APOTEX INC.: PRODUCT PORTFOLIO
  • TABLE 102.APOTEX INC.: NET SALES
  • TABLE 103.APOTEX INC.: KEY STRATERGIES
  • TABLE 104.AUROBINDO PHARMA LTD: COMPANY SNAPSHOT
  • TABLE 105.AUROBINDO PHARMA LTD: OPERATING SEGMENTS
  • TABLE 106.AUROBINDO PHARMA LTD: PRODUCT PORTFOLIO
  • TABLE 107.AUROBINDO PHARMA LTD: NET SALES
  • TABLE 108.AUROBINDO PHARMA LTD: KEY STRATERGIES
  • TABLE 109.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 110.ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 111.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 112.ELI LILLY AND COMPANY: NET SALES
  • TABLE 113.ELI LILLY AND COMPANY: KEY STRATERGIES
  • TABLE 114.DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 115.DR. REDDY'S LABORATORIES LTD.: OPERATING SEGMENTS
  • TABLE 116.DR. REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 117.DR. REDDY'S LABORATORIES LTD.: NET SALES
  • TABLE 118.DR. REDDY'S LABORATORIES LTD.: KEY STRATERGIES
  • TABLE 119.SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 120.SUN PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS
  • TABLE 121.SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 122.SUN PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES
  • TABLE 123.SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
  • TABLE 124.TORRENT GROUP: COMPANY SNAPSHOT
  • TABLE 125.TORRENT GROUP: OPERATING SEGMENTS
  • TABLE 126.TORRENT GROUP: PRODUCT PORTFOLIO
  • TABLE 127.TORRENT GROUP: NET SALES
  • TABLE 128.TORRENT GROUP: KEY STRATERGIES
  • TABLE 129.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 130.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS
  • TABLE 131.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 132.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES
  • TABLE 133.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
  • TABLE 134.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 135.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 136.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 137.NOVARTIS AG: NET SALES
  • TABLE 138.NOVARTIS AG: KEY STRATERGIES
  • TABLE 139.VIATRIS: COMPANY SNAPSHOT
  • TABLE 140.VIATRIS: OPERATING SEGMENTS
  • TABLE 141.VIATRIS: PRODUCT PORTFOLIO
  • TABLE 142.VIATRIS: NET SALES
  • TABLE 143.VIATRIS: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.OLANZAPINE MARKET SEGMENTATION
  • FIGURE 2.OLANZAPINE MARKET,2021-2031
  • FIGURE 3.OLANZAPINE MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.OLANZAPINE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.OLANZAPINE MARKET,BY APPLICATION,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF SCHIZOPHRENIA OLANZAPINE MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF BIPOLAR DISORDER OLANZAPINE MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF OTHERS OLANZAPINE MARKET,2021-2031(%)
  • FIGURE 16.OLANZAPINE MARKET,BY ROUTE OF ADMINISTRATION,2021(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ORAL OLANZAPINE MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF PARENTERAL OLANZAPINE MARKET,2021-2031(%)
  • FIGURE 19.OLANZAPINE MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES OLANZAPINE MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES OLANZAPINE MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS OLANZAPINE MARKET,2021-2031(%)
  • FIGURE 23.OLANZAPINE MARKET BY REGION,2021
  • FIGURE 24.U.S. OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 25.CANADA OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 26.MEXICO OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 27.GERMANY OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 28.FRANCE OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 29.UK OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 30.ITALY OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 31.SPAIN OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 32.REST OF EUROPE OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 33.JAPAN OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 34.CHINA OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 35.INDIA OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 36.AUSTRALIA OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 37.SOUTH KOREA OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 38.REST OF ASIA-PACIFIC OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 39.BRAZIL OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 40.SAUDI ARABIA OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 41.SOUTH AFRICA OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 42.REST OF LAMEA OLANZAPINE MARKET,2021-2031($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 46.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47.COMPETITIVE DASHBOARD
  • FIGURE 48.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 49.ALKERMES, INC..: NET SALES ($MILLION)
  • FIGURE 50.APOTEX INC..: NET SALES ($MILLION)
  • FIGURE 51.AUROBINDO PHARMA LTD.: NET SALES ($MILLION)
  • FIGURE 52.ELI LILLY AND COMPANY.: NET SALES ($MILLION)
  • FIGURE 53.DR. REDDY'S LABORATORIES LTD..: NET SALES ($MILLION)
  • FIGURE 54.SUN PHARMACEUTICAL INDUSTRIES LIMITED.: NET SALES ($MILLION)
  • FIGURE 55.TORRENT GROUP.: NET SALES ($MILLION)
  • FIGURE 56.TEVA PHARMACEUTICAL INDUSTRIES LIMITED.: NET SALES ($MILLION)
  • FIGURE 57.NOVARTIS AG.: NET SALES ($MILLION)
  • FIGURE 58.VIATRIS.: NET SALES ($MILLION)